MA46690A - Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 - Google Patents

Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2

Info

Publication number
MA46690A
MA46690A MA046690A MA46690A MA46690A MA 46690 A MA46690 A MA 46690A MA 046690 A MA046690 A MA 046690A MA 46690 A MA46690 A MA 46690A MA 46690 A MA46690 A MA 46690A
Authority
MA
Morocco
Prior art keywords
triazolo
pyrimidine compounds
pde2 inhibitors
pde2
inhibitors
Prior art date
Application number
MA046690A
Other languages
English (en)
Inventor
Peter Jacobus Johannes Antonius Buijnsters
Henricus Jacobus Maria Gijsen
Gary John Tresadern
Den Keybus Frans Alfons Maria Van
Roosbroeck Yves Emiel Maria Van
Adriana Ingrid Velter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA46690A publication Critical patent/MA46690A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA046690A 2016-11-02 2017-10-31 Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 MA46690A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16196936 2016-11-02

Publications (1)

Publication Number Publication Date
MA46690A true MA46690A (fr) 2019-09-11

Family

ID=57223577

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046690A MA46690A (fr) 2016-11-02 2017-10-31 Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2

Country Status (13)

Country Link
US (1) US11319321B2 (fr)
EP (1) EP3535268B1 (fr)
JP (1) JP7018944B2 (fr)
KR (1) KR20190067788A (fr)
CN (1) CN109890824B (fr)
AU (1) AU2017353313C1 (fr)
BR (1) BR112019008604A2 (fr)
CA (1) CA3038913A1 (fr)
EA (1) EA039847B1 (fr)
ES (1) ES2912264T3 (fr)
MA (1) MA46690A (fr)
MX (1) MX390505B (fr)
WO (1) WO2018083101A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122423C2 (uk) 2015-11-02 2020-11-10 Янссен Фармацевтика Нв [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИН-7-ІЛЬНА СПОЛУКА
UA125302C2 (uk) 2016-11-02 2022-02-16 Янссен Фармацевтика Нв Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2
KR20190071721A (ko) 2016-11-02 2019-06-24 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
MA46690A (fr) 2016-11-02 2019-09-11 Janssen Pharmaceutica Nv Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
EP3585790A1 (fr) * 2017-02-27 2020-01-01 Janssen Pharmaceutica NV Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
CN115960101B (zh) * 2022-12-30 2024-10-18 海南大学 7-氧代-4,5,6,7-四氢吡唑并吡啶酰胺类化合物及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06509069A (ja) 1991-06-27 1994-10-13 バージニア・コモンウェルス・ユニバーシティ シグマレセプターリガンドおよびその用途
DE69934093T2 (de) 1998-01-27 2007-06-21 Aventis Pharmaceuticals Inc. SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
MXPA05003471A (es) 2002-10-03 2005-07-01 Vertex Pharma Derivados de piperazina y piperadina para el tratamiento de enfermedades neurologicas.
WO2004108136A1 (fr) 2003-06-04 2004-12-16 Vernalis (Cambridge) Limited Triazolo`1,5-a!pyrimidines et leur utilisation en medecine
JP2007526894A (ja) 2003-07-16 2007-09-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グリコーゲンシンターゼキナーゼ３インヒビターとしてのトリアゾロピリミジン誘導体
US7728025B2 (en) 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
WO2007113136A1 (fr) 2006-03-30 2007-10-11 Basf Aktiengesellschaft Utilisation de triazolopyrimidines substituées dans la lutte contre des champignons phytopathogènes
JP2007332061A (ja) 2006-06-14 2007-12-27 Nippon Kayaku Co Ltd 新規ピラゾロ［１，５−ａ］ピリミジン誘導体及びその用途
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US7928103B2 (en) 2006-10-17 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP2010065024A (ja) * 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
AP2013007070A0 (en) 2011-02-23 2013-08-31 Pfizer Imidazo[5,1-f][1,2,4] triazines for the treatment of neurological disorders
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
EP2758375A1 (fr) 2011-09-23 2014-07-30 Advinus Therapeutics Limited Composés amides, compositions et applications de ceux-ci
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
IN2014DN07384A (fr) 2012-03-09 2015-04-24 Lexicon Pharmaceuticals Inc
EP3110794A1 (fr) 2014-02-27 2017-01-04 Merck Patent GmbH Composés hétérocycliques en tant qu'inhibiteurs du canal nav, et leurs utilisations
CA2942997C (fr) 2014-03-19 2022-09-13 Boehringer Ingelheim International Gmbh Inhibiteurs de sik de type heteroaryle
EP3134413B1 (fr) 2014-04-23 2019-09-11 Dart NeuroScience (Cayman) Ltd. Composés de [1,2,4]triazolo[1,5-a]pyrimidin-7-yle substitués utilisables en tant qu'inhibiteurs de pde2
WO2015162515A1 (fr) 2014-04-25 2015-10-29 Pfizer Inc. Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
CN105566321B (zh) 2014-10-29 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
TWI530688B (zh) 2014-11-18 2016-04-21 彭顯智 製備微奈米探針設備及方法
CN105753817A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 一类取代氮杂环衍生物及其应用
WO2016145614A1 (fr) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Composés de triazolyl pyrimidinone en tant qu'inhibiteurs de pde2
WO2017000276A1 (fr) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Composés hétérocycliques bicycliques utilisés en tant qu'inhibiteurs de pde2
WO2017000277A1 (fr) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclo-composés de triazole substitués utilisés en tant qu'inhibiteurs de pde2
US20180305334A1 (en) 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
UA122423C2 (uk) 2015-11-02 2020-11-10 Янссен Фармацевтика Нв [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИН-7-ІЛЬНА СПОЛУКА
WO2017157882A1 (fr) 2016-03-14 2017-09-21 Université Catholique de Louvain Inhibiteurs de la voie de biosynthèse de la sérine
MA46690A (fr) 2016-11-02 2019-09-11 Janssen Pharmaceutica Nv Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
KR20190071721A (ko) 2016-11-02 2019-06-24 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
UA125302C2 (uk) 2016-11-02 2022-02-16 Янссен Фармацевтика Нв Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2
CN110312716A (zh) 2016-12-16 2019-10-08 詹森药业有限公司 双环oga抑制剂化合物

Also Published As

Publication number Publication date
AU2017353313A1 (en) 2019-04-18
BR112019008604A2 (pt) 2019-07-09
CN109890824A (zh) 2019-06-14
JP2019532990A (ja) 2019-11-14
US11319321B2 (en) 2022-05-03
CN109890824B (zh) 2022-05-24
EP3535268B1 (fr) 2022-02-09
ES2912264T3 (es) 2022-05-25
JP7018944B2 (ja) 2022-02-14
AU2017353313B2 (en) 2021-09-16
WO2018083101A1 (fr) 2018-05-11
EA039847B1 (ru) 2022-03-18
KR20190067788A (ko) 2019-06-17
MX2019005123A (es) 2019-06-20
EA201991094A1 (ru) 2019-09-30
US20200055858A1 (en) 2020-02-20
AU2017353313C1 (en) 2022-06-09
MX390505B (es) 2025-03-20
CA3038913A1 (fr) 2018-05-11
EP3535268A1 (fr) 2019-09-11

Similar Documents

Publication Publication Date Title
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu&#39;inhibiteurs de la kinase ret
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu&#39;inhibiteurs de jak
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
MA50375A (fr) Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu&#39;inhibiteurs pde2
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
EP3328840A4 (fr) Composés bicycliques triazolo substitués en tant qu&#39;inhibiteurs de pde2
DK3322706T3 (da) Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
LT3555097T (lt) Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
SG11201801365YA (en) NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF
ME03672B (fr) 1h-pyrazolo [4,3-b]pyridines en tant qu&#39;inhibiteurs de pde1
MA43021A (fr) Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu&#39;inhibiteurs doubles de dyrk1/clk1
EP2525659A4 (fr) Composés pyrazolo[1,5-a]pyrimidines en tant qu&#39;inhibiteurs de mtor
EP3722298A4 (fr) Dérivé de pyrrolo(pyrazolo)pyrimidine utilisé en tant qu&#39;inhibiteur de lrrk2
EP3380475A4 (fr) Dérivés d&#39;octahydropyrrolo [3, 4-c
EP3096762C0 (fr) Pyrazolo[1,5-a]pyrimidines comme composés antiviraux
EP3508487A4 (fr) COMPOSÉ DE PYRAZOLO [1,5-a]PYRIMIDINE
EP3319966A4 (fr) Composés hétérocycliques bicycliques utilisés comme inhibiteurs de pde2
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
EP3551630A4 (fr) Dérivés d&#39;imidazo [1,5-a]pyrazine en tant qu&#39;inhibiteurs de pi3kdelta
EP3679042A4 (fr) Dérivés d&#39;imidazo[1,5-a]pyrazine en tant qu&#39;inhibiteurs de pi3kdelta
EP3313852A4 (fr) Composés bicycliques pyrazolo/imidazolo substitués en tant qu&#39;inhibiteurs de pde2
IL260536B (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
HUE048370T2 (hu) Eljárás 4,5,6,7-tetrahidroizoxazolo[5,4-c] piridin-3-ol elõállítására